Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, Gudi R, Saber H, Shord S, Bullock J, Marathe D, Mehrotra N, Hsieh LS, Ghosh D, Brown J, Kane RC, Justice R, Kaminskas E, Farrell AT, Pazdur R. Miller BW, et al. Clin Cancer Res. 2015 Apr 1;21(7):1525-9. doi: 10.1158/1078-0432.CCR-14-2522. Epub 2015 Feb 2. Clin Cancer Res. 2015. PMID: 25645861
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Lee HZ, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N, Ko CW, Nie L, Shapiro M, Tolnay M, Kane RC, Kaminskas E, Justice R, Farrell AT, Pazdur R. Lee HZ, et al. Among authors: miller bw. Clin Cancer Res. 2014 Aug 1;20(15):3902-7. doi: 10.1158/1078-0432.CCR-14-0516. Epub 2014 May 13. Clin Cancer Res. 2014. PMID: 24824310 Clinical Trial.
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung TH, Kessler Z, Woods C, Kim B, Miller BW, Wernecke M, Kim C, McKean S, Gelperin K, MaCurdy TE, Kelman JA, Graham DJ. Bird ST, et al. Among authors: miller bw. JAMA Oncol. 2020 Feb 1;6(2):248-254. doi: 10.1001/jamaoncol.2019.3994. JAMA Oncol. 2020. PMID: 31855259 Free PMC article. Clinical Trial.
Biodiversity loss reduces global terrestrial carbon storage.
Weiskopf SR, Isbell F, Arce-Plata MI, Di Marco M, Harfoot M, Johnson J, Lerman SB, Miller BW, Morelli TL, Mori AS, Weng E, Ferrier S. Weiskopf SR, et al. Among authors: miller bw. Nat Commun. 2024 May 22;15(1):4354. doi: 10.1038/s41467-024-47872-7. Nat Commun. 2024. PMID: 38778013 Free PMC article.
Bringing the Nature Futures Framework to life: creating a set of illustrative narratives of nature futures.
Durán AP, Kuiper JJ, Aguiar APD, Cheung WWL, Diaw MC, Halouani G, Hashimoto S, Gasalla MA, Peterson GD, Schoolenberg MA, Abbasov R, Acosta LA, Armenteras D, Davila F, Denboba MA, Harrison PA, Harhash KA, Karlsson-Vinkhuyzen S, Kim H, Lundquist CJ, Miller BW, Okayasu S, Pichs-Madruga R, Sathyapalan J, Saysel AK, Yu D, Pereira LM. Durán AP, et al. Among authors: miller bw. Sustain Sci. 2023 May 4:1-20. doi: 10.1007/s11625-023-01316-1. Online ahead of print. Sustain Sci. 2023. PMID: 37363310 Free PMC article.
A Conceptual Framework to Integrate Biodiversity, Ecosystem Function, and Ecosystem Service Models.
Weiskopf SR, Myers BJE, Arce-Plata MI, Blanchard JL, Ferrier S, Fulton EA, Harfoot M, Isbell F, Johnson JA, Mori AS, Weng E, HarmáCˇková ZV, Londoño-Murcia MC, Miller BW, Pereira LM, Rosa IMD. Weiskopf SR, et al. Among authors: miller bw. Bioscience. 2022 Sep 1;72(11):1062-1073. doi: 10.1093/biosci/biac074. eCollection 2022 Nov. Bioscience. 2022. PMID: 36506699 Free PMC article. Review.
155 results